You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Table 1.  

Isolate and Patient Characteristics for 300 Veterans who had Staphylococcus aureus bacteremia
at 4 Veterans Affairs Medical Centers, USA, 2004–2008*

Table 2.  

Infection Characteristics for 300 Veterans who had Staphylococcus aureus Bacteremia
at 4 Veterans Affairs Medical Centers, USA, 2004–2008

Table 3.  

Patient and Infection Characteristics for 300 Veterans with Staphylococcus aureus Bacteremia
and Association with Illicit Drug Use at 4 Veterans Affairs Medical Centers, USA, 2004–2008*

Table 4.  

Patient and Infection Characteristics for 300 Veterans with Staphylococcus aureus Bacteremia
and Association with USA300 MRSA at 4 Veterans Affairs Medical Centers, USA, 2004–2008*

Table 5.  

Independent Risk Factors for USA300 MRSA Bacteremia
Among 300 Veterans at 4 Veterans Affairs Medical Centers, USA, 2004–2008*

CME

Illicit Drug Use and the Risk of USA300 Methicillin-Resistant Staphylococcus aureus Infections With Bacteremia

  • Authors: Kristen M. Kreisel, PhD; J. Kristie Johnson, PhD; O. Colin Stine, PhD; Michelle D. Shardell, PhD; Alan J. Lesse, MD; Fred M. Gordin, MD; Michael W. Climo, MD; Mary-Claire Roghmann, MD, MS
  • CME Released: 8/16/2010
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 8/16/2011, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for primary care clinicians, infectious disease specialists, and other specialists who care for patients at risk for community-acquired MRSA infection.

The goal of this activity is to review the epidemiology of community-acquired MRSA and its changing pattern of acquisition.

Upon completion of this activity, participants will be able to:

  1. Examine the association of illicit drug use with USA300 MRSA infection, including risk factors for acquisition and transmission
  2. Describe characteristics of illicit drug users who acquire MRSA and the changing pattern of risk from 2004 to 2008 in the United States with implications for management and prevention


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • J. Kristie Johnson, PhD

    University of Maryland, Baltimore

    Disclosures

    Disclosure: J. Kristie Johnson, PhD, has disclosed the following relationships:
    Received grants for clinical research from: Becton, Dickinson and Company

  • O. Colin Stine, PhD

    University of Maryland, Baltimore

    Disclosures

    Disclosure: O. Colin Stine, PhD, has disclosed no relevant financial relationships.

  • Michelle D. Shardell, PhD

    University of Maryland, Baltimore

    Disclosures

    Disclosure: Michelle D. Shardell, PhD, has disclosed no relevant financial relationships.

  • Eli N. Perencevich, MD, MS

    University of Maryland, Baltimore, Maryland; VA Maryland Health Care System, Baltimore, Maryland

    Disclosures

    Disclosure: Eli N. Perencevich, MD, MS, has disclosed the following relationships:
    Received grants for clinical support from: Pfizer Inc.

  • Alan J. Lesse, MD

    VA Western New York Healthcare System, Buffalo, New York; University at Buffalo, Buffalo, New York

    Disclosures

    Disclosure: Alan J. Lesse, MD, has disclosed no relevant financial relationships.

  • Fred M. Gordin, MD

    Washington DC VA Medical Center, Washington, DC; George Washington University, Washington, DC

    Disclosures

    Disclosure: Fred M. Gordin, MD, has disclosed no relevant financial relationships.

  • Michael W. Climo, MD

    Hunter Holmes McGuire VA Medical Center, Richmond, Virginia; Medical College of Virginia at Virginia Commonwealth University, Richmond, Virginia

    Disclosures

    Disclosure: Michael W. Climo, MD, has disclosed the following relationships:
    Served as an advisor or consultant for: Biosynexus Incorporated
    Received grants for clinical research from: Biosynexus Incorporated

  • Mary-Claire Roghmann, MD, MS

    University of Maryland, Baltimore, Maryland; VA Maryland Health Care System, Baltimore, Maryland

    Disclosures

    Disclosure: Mary-Claire Roghmann, MD, MS, has disclosed no relevant financial relationships.

Editor(s)

  • Carol Snarey

    Copyeditor, Emerging Infectious Diseases

    Disclosures

    Disclosure: Carol Snarey has disclosed no relevant financial relationships.

CME Author(s)

  • Désirée Lie, MD, MSEd

    Clinical Professor of Family Medicine, Director of Research and Faculty Development, University of California, Irvine at Orange, California

    Disclosures

    Disclosure: Désirée Lie, MD, MSEd, has disclosed the following relevant financial relationship:
    Served as a nonproduct speaker for: "Topics in Health" for Merck Speaker Services

CME Reviewer(s)

  • Sarah Fleischman

    CME Program Manager, Medscape, LLC

    Disclosures

    Disclosure: Sarah Fleischman has disclosed no relevant financial relationships.

  • Laurie E. Scudder, DNP, NP

    CME Accreditation Coordinator, Medscape, LLC

    Disclosures

    Disclosure: Laurie E. Scudder, DNP, NP, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

    Medscape, LLC designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. MedscapeCME encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME

Illicit Drug Use and the Risk of USA300 Methicillin-Resistant Staphylococcus aureus Infections With Bacteremia: Discussion

processing....

Discussion

In this multicenter study, illicit drug users were more likely to have a bacteremic infection caused by USA300 MRSA than any other type of S. aureus, regardless of when the patient's infection occurred. The data were consistent with a decrease in the association over the study period, from a RR of 4.63 in the early years of the study to a RR of 2.45 in the late years of the study.

The finding that the association between illicit drug use and USA300 MRSA bacteremia declined over the study period is clinically important. This illustrates that, although USA300 MRSA infections emerged in drug users, this epidemic is now spreading to other populations. The illicit drug-using population has been recognized as a reservoir for USA300 MRSA.[14] The spread to other populations observed in this study could be the result of transmission and dissemination of the strains among at-risk patients in the community, as suggested by the fact that 43% of cases of bacteremia were not classified as nosocomial infections in this population. This means that patients who have bacteremia could have acquired the bacteria during a previous healthcare exposure or in the community. In contrast, illicit drug users who are colonized or infected with USA300 MRSA could serve as a reservoir for transmission to other patient populations while hospitalized for their infections.[12-14,26,27] Further investigation is warranted.

The increased risk of acquiring an infection caused by USA300 MRSA among illicit drug users found in this study is consistent with the findings of other studies. Gilbert et al. reported that the incidence of USA300 MRSA was higher among high-risk case-patients (defined as including a history of illicit drug use) than low-risk case-patients.[28]

In a study of the New York State Prison System, inmates with drug charges were more likely to have an infection. The USA300 MRSA strain was the predominant clone that caused infections in inmates.[29] Although our study used different sampling methods and slightly different case definitions than previous studies, the conclusions are the same. Illicit drug users are at increased risk for an infection caused by USA300 MRSA compared with persons who do not use illicit drugs.

The association between illicit drug use and USA300 MRSA bacteremia could be explained by the fact that S. aureus infections are a common complication of drug use. Drug users are colonized with S. aureus more often than persons who do not use drugs.[13,14] Colonization is a main risk factor for infection; the patient is usually infected with his own colonizing strain. In addition, invasive infections can occur from transfer of the colonizing strain directly into the patient's bloodstream.[13,14] If USA300 MRSA is the colonizing strain, the frequent inhalation or injection of drugs could transfer this strain into the bloodstream to cause a life-threatening invasive infection.

Our study has some limitations. First, data regarding illicit drug use at the various VAMCs is based on self-report. Information regarding drug use is of a sensitive nature and, therefore, subject to recall bias. Also, to locate in the patient's electronic medical record whether the drugs were injected depended on whether the healthcare professional specifically asked and made note of this, a situation which is prone to information bias. Second, the ICD-9 codes used to define illicit drug use are imperfect measurements because they are used for insurance billing, rather than clinical purposes. Also, if any illicit drug-using patients were not hospitalized in the year before enrollment, or if drug-using patients did not report drug use during the hospitalization of interest, drug use would have been misclassified. In addition, using ICD-9 codes to define drug use up to 1 year before admission may not accurately measure current patterns of drug use in patients; the result would be a differential misclassification of exposure and could overestimate or underestimate the true association. Third, the study population was comprised only of veterans. The use of such a distinct population could reduce the generalizability of these findings. However, the relationship of illicit drug use with USA300 MRSA among veterans would likely not differ from the relationship among nonveterans, so the results should still be generalizable. Finally, USA300 MRSA isolates could have been misclassified with the use of our laboratory algorithm; however, the validation of isolates by PFGE, which showed a high sensitivity and specificity, makes this unlikely.

This study has several strengths. First, the use of more than 1 study site helped improve the generalizability of these findings. For example, we evaluated whether any of the associations observed may have been due to differences between the 4 VAMCs (this analysis was in response to a finding that patients from the Buffalo VAMC were less likely to be illicit drug users and less likely to have an infection due to USA300 MRSA). After excluding all patients from the Buffalo VAMC from the analysis, we found no difference from the results of the entire cohort (data not shown); therefore, we chose to present the combined data. Additionally, the electronic medical record system used throughout the Veterans Health Administration is known to be a valuable asset because of the completeness of data and for the amount of time it has stored information. The use of this system for chart review helped decrease selection and information bias. Finally, the findings of this study are strengthened because we could provide molecular typing data for each of the isolates.

In conclusion, the data from this study showed that illicit drug users are more likely to acquire a bacteremic infection caused by USA300 MRSA than by all other S. aureus strains. The decrease observed in the association of illicit drug use and USA300 MRSA bacteremia over the study period suggests that the USA300 MRSA epidemic is now spreading from illicit drug users to other patient populations. Focusing infection control efforts on high-risk groups such as illicit drug users might slow the progression of the USA300 MRSA epidemic in areas of the country where the association between illicit drug use and USA300 is still high.